华东医药2024年半年度报告（英文版）

2024 Semi-Annual Report of Huadong Medicine Co., Ltd. 1 Huadong Medicine Co., Ltd. Semi-Annual Report 2024 August 16, 2024 2024 Semi-Annual Report of Huadong Medicine Co., Ltd. 2 Section I. Important Declaration, Contents and Definitions The Board of Directors, Board of Supervisors, directors, supervisors and senior managers of Huadong Medicine Co., Ltd. (hereinafter referred to as the “Company”) hereby guarantee that the information presented in this semi-annual report is authentic, accurate and complete, and free of any false records, misleading statements or material omissions, and shall undertake individual and joint legal liabilities. Lv Liang, the Company’s legal representative and the officer in charge of accounting, and Qiu Renbo, head of accounting department (accounting supervisor) hereby declare and guarantee that the financial statements in this semi-annual report are authentic, accurate and complete. All directors have attended the Board of Directors meeting to review this semi-annual report. The future plans, development strategies and other forward-looking statements in this semi-annual report shall not be considered as substantial commitment of the Company to investors. Investors and related parties should be fully aware of the risks, and understand the differences between plans, forecasts and commitments. The risks the Company faces in operation include industry policy and product price reduction risk, new drug R&D risk, investment and M&A risk and exchange rate fluctuation risk. For details, please refer to “X. Risks and Countermeasures” in “Section III. Management’s Discussion and Analysis”. 2024 Semi-Annual Report of Huadong Medicine Co., Ltd. 3 Therefore, investors are kindly reminded to pay attention to possible investment risks. The dividend distribution scheme approved at the meeting of the Board of Directors is as follows: On the basis of 1,754,262,548 shares that are obtained after removing 65,000 restricted shares that have not been repurchased and canceled from the total share capital of 1,754,327,548 shares of the Company, 3.50 yuan (before tax) of cash dividends per ten common shares will be distributed to all shareholders; a total of 0 bonus share (before tax) will be issued; and no capital reserve will be converted to increase the capital stock. According to “Stock Listing Rules of the Shenzhen Stock Exchange”, if listed companies have both Chinese and other language version of public notice, they should ensure the content of both versions are the same. In the case of discrepancy, the original version in Chinese shall prevail. 2024 Semi-Annual Report of Huadong Medicine Co., Ltd. 4 Contents Section I. Important Declaration, Contents and Definitions ............................................................................... 2 Section II. Company Profile and Key Financial Indicators ................................................................................. 9 Section III. Management's Discussion and A